314 related articles for article (PubMed ID: 15011781)
1. Hematopoietic stem cell transplant as a platform for tumor immunotherapy.
Fuchs EJ; Whartenby KA
Curr Opin Mol Ther; 2004 Feb; 6(1):48-53. PubMed ID: 15011781
[TBL] [Abstract][Full Text] [Related]
2. New approaches to treating malignances with stem cell transplantation.
Margolis J; Borrello I; Flinn IW
Semin Oncol; 2000 Oct; 27(5):524-30. PubMed ID: 11049020
[TBL] [Abstract][Full Text] [Related]
3. Experimental evidence of interleukin-2 activity in bone marrow transplantation.
Mazumder A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S37-42. PubMed ID: 9457392
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
Zöller M; Matzku S
Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
[TBL] [Abstract][Full Text] [Related]
6. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
[TBL] [Abstract][Full Text] [Related]
7. [Allogeneic hematopoietic stem cell transplantation for solid tumors].
Kanda Y
Rinsho Ketsueki; 2004 Mar; 45(3):189-94. PubMed ID: 15103931
[No Abstract] [Full Text] [Related]
8. Immunotherapy by allogeneic stem cell transplantation.
Ringdén O
Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for malignant tumors using combination of allogeneic intra-bone marrow-bone marrow transplantation, donor lymphocyte infusion and dendritic cells.
Mukaide H; Adachi Y; Koike-Kiriyama N; Suzuki Y; Minamino K; Iwasaki M; Tsuda M; Nakano K; Koike Y; Shigematsu A; Kamiyama Y; Ikehara S
Int J Oncol; 2007 Jun; 30(6):1309-15. PubMed ID: 17487350
[TBL] [Abstract][Full Text] [Related]
10. Manipulation of the stem cell as a target for hematologic malignancies.
Ballen KK; Becker PS; Stewart FM; Quesenberry PJ
Semin Oncol; 2000 Oct; 27(5):512-23. PubMed ID: 11049019
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of cancer for the elderly patient: does allogeneic bone marrow transplantation after nonmyeloablative conditioning provide a new option?
Zöller M
Cancer Immunol Immunother; 2004 Aug; 53(8):659-76. PubMed ID: 15067430
[TBL] [Abstract][Full Text] [Related]
12. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
Resnick IB; Shapira MY; Slavin S
Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic cell-mediated immunotherapy at the stage of minimal residual disease following high-dose chemotherapy supported by autologous stem cell transplantation.
Slavin S
Acta Haematol; 2005; 114(4):214-20. PubMed ID: 16269861
[TBL] [Abstract][Full Text] [Related]
14. Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy.
Espinoza-Delgado I; Childs RW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):865-75. PubMed ID: 15485320
[TBL] [Abstract][Full Text] [Related]
15. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?
Har-Noy M; Slavin S
Med Hypotheses; 2008; 70(6):1186-92. PubMed ID: 18054441
[TBL] [Abstract][Full Text] [Related]
16. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.
Neelapu SS; Munshi NC; Jagannath S; Watson TM; Pennington R; Reynolds C; Barlogie B; Kwak LW
Bone Marrow Transplant; 2005 Aug; 36(4):315-23. PubMed ID: 15968284
[TBL] [Abstract][Full Text] [Related]
17. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance.
Kline J; Subbiah S; Lazarus HM; van Besien K
Bone Marrow Transplant; 2008 Mar; 41(6):505-13. PubMed ID: 18026144
[TBL] [Abstract][Full Text] [Related]
18. Donor lymphocyte infusion. An adaptive cellular immunotherapy for treatment of hematological malignancies.
Owaidah TM
Saudi Med J; 2003 Feb; 24(2):138-41. PubMed ID: 12682675
[TBL] [Abstract][Full Text] [Related]
19. A new strategy for treatment of malignant tumor: intra-bone marrow-bone marrow transplantation plus CD4- donor lymphocyte infusion.
Suzuki Y; Adachi Y; Minamino K; Zhang Y; Iwasaki M; Nakano K; Koike Y; Ikehara S
Stem Cells; 2005 Mar; 23(3):365-70. PubMed ID: 15749931
[TBL] [Abstract][Full Text] [Related]
20. Autologous hematopoietic stem cell transplantation for pediatric solid tumors.
Hale GA
Expert Rev Anticancer Ther; 2005 Oct; 5(5):835-46. PubMed ID: 16221053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
